About Zy Therapeutics
Targeting the Root Cause of Rare CNS Disorders
Zy Therapeutics is a rare disease biotech developing the first therapy to directly target brain calcifications—an overlooked driver of seizures, cognitive decline, and disability in rare CNS disorders.
Our work is guided by both professional experience and personal connection to the conditions we aim to treat. We see the daily burden faced by patients and families living with seizures, developmental challenges, and the uncertainty of progressive neurological disease.
By improving the delivery of a proven, safe bisphosphonate molecule, we aim to deliver the first disease-modifying treatment for many of these devastating conditions. We are committed to rigorous science, patient advocacy, and a collaborative approach to bringing hope and new solutions to the rare disease community.
Our Mission
Providing Hope by Making Brain Calcification
a Treatable Target
At Zy Therapeutics, our mission is to transform brain calcification into a treatable target—bringing hope to patients and families living with rare central nervous system (CNS) disorders.
As scientists, clinicians, and parents personally touched by neurological disease, we share a deep commitment to changing outcomes for patients facing seizures, developmental challenges, and cognitive decline caused by brain calcification.
Through decades of clinical epilepsy research, translational neuroscience, and patient advocacy, our team has witnessed both the burden of these conditions and the opportunity for meaningful intervention.
We are driven by a single goal: to turn scientific insight into life-changing therapies for those who currently have none.